(Q37461418)

20 August 2017

1 reference

title

Pharmacologic therapy for intermittent claudication (English)

1 reference

20 August 2017

1 reference

1 reference

Paul P Dobesh

1

1 reference

20 August 2017

Zachary A Stacy

series ordinal

2

1 reference

20 August 2017

Emily L Persson

series ordinal

3

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

29

1 reference

20 August 2017

526-553

1 reference

20 August 2017

5

1 reference

Critical issues in peripheral arterial disease detection and management: a call to action

20 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

The prevalence of peripheral arterial disease in a defined population

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Peripheral arterial disease detection, awareness, and treatment in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Epidemiology and pathophysiology of lower extremity peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

The prevalence of peripheral arterial disease in a racially diverse population

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Quality of life in patients with intermittent claudication using the World Health Organisation (WHO) questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Evaluating effects of method of administration on Walking Impairment Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Metabolic Activity of Skeletal Muscle in Patients with Peripheral Arterial Insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Meeting the challenge of peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Medical treatment of peripheral arterial disease and claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Antithrombotic potential of pentoxifylline. A hemorheologically active drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effects of Flunarizine and Pentoxifylline on Walking Distance and Blood Rheology in Claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Intermittent claudication: a double-blind crossover trial of pentoxifylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Venous thrombosis from air travel: the LONFLIT3 study--prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Conservative management of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Pentoxifylline for intermittent claudication. A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Drug treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

The US experience with cilostazol in treating intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Analysis of the cilostazol safety database

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Naftidrofuryl in chronic arterial disease. Results of a controlled multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Carnitine and peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

European multicenter study on propionyl-L-carnitine in intermittent claudication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

L-arginine supplementation in peripheral arterial disease: no benefit and possible harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Complementary therapies for peripheral arterial disease: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Alternative therapy bias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

A long-term study of policosanol in the treatment of intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Does fish oil lower blood pressure? A meta-analysis of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Does supplementation of diet with 'fish oil' reduce blood pressure? A meta-analysis of controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Statin use and functional decline in patients with and without peripheral arterial disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-blinded, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

A dose-effect study of beraprost sodium in intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Growth factors for therapeutic angiogenesis in peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Cardiovascular gene therapy: current status and therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermitt

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Chelation therapy for peripheral arterial occlusive disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Blood flow properties and walking performance in chronic arterial occlusive disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Costs and Medical Care Consequences Associated with the Diagnosis of Peripheral Arterial Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.5.526

Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial

21 January 2018

1 reference

3 January 2024

https://opencitations.net/index/api/v1/citations/10.7326/0003-4819-144-9-200605020-00009

Identifiers

DOI

10.1592/PHCO.29.5.526

1 reference

20 August 2017

1 reference